Relay Therapeutics, Inc. (RLAY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '21: 3M Q1 '22: 2.5M Q2 '22: 2M Q3 '22: 1.7M Q4 '22: 1.4M Q1 '23: 1.2M Q2 '23: 942K Q3 '23: 25.8M Q4 '23: 25.5M Q1 '24: 35.3M Q2 '24: 35.2M Q3 '24: 10M Q4 '24: 10M Q1 '25: 7.7M Q2 '25: 8.4M Q3 '25: 8.4M Q4 '25: 15.4M Q1 '26: 10.7M Q2 '26: 10.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '19: -84M Q1 '20: -94.1M Q2 '20: -101.9M Q3 '20: -116.6M Q4 '20: -55.8M Q1 '21: -71.7M Q2 '21: -237.6M Q3 '21: -262M Q4 '21: -364.7M Q1 '22: -385M Q2 '22: -269.2M Q3 '22: -294.1M Q4 '22: -299.3M Q1 '23: -337.7M Q2 '23: -366M Q3 '23: -353.7M Q4 '23: -373M Q1 '24: -362.2M Q2 '24: -356.9M Q3 '24: -379.7M Q4 '24: -372.5M Q1 '25: -367M Q2 '25: -343.1M Q3 '25: -327.1M Q4 '25: -302.7M Q1 '26: -296.5M Q2 '26: -310.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '19: -75.3M Q1 '20: -86M Q2 '20: -95.2M Q3 '20: -111.6M Q4 '20: -52.4M Q1 '21: -69.7M Q2 '21: -236.4M Q3 '21: -261.1M Q4 '21: -363.9M Q1 '22: -383.7M Q2 '22: -267.1M Q3 '22: -290.5M Q4 '22: -290.5M Q1 '23: -322.7M Q2 '23: -344.4M Q3 '23: -326M Q4 '23: -342M Q1 '24: -329.1M Q2 '24: -322.8M Q3 '24: -345.2M Q4 '24: -337.7M Q1 '25: -333.4M Q2 '25: -311.5M Q3 '25: -297.6M Q4 '25: -276.5M Q1 '26: -272.7M Q2 '26: -286M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '20: -83.4M Q3 '20: -90M Q4 '20: -102.5M Q1 '21: -33.5M Q2 '21: -40.8M Q3 '21: -70M Q4 '21: -74.4M Q1 '22: -170.2M Q2 '22: -199.2M Q3 '22: -212.1M Q4 '22: -229.5M Q1 '23: -247.4M Q2 '23: -259M Q3 '23: -268.2M Q4 '23: -300.3M Q1 '24: -283.5M Q2 '24: -280.7M Q3 '24: -280.4M Q4 '24: -249.1M Q1 '25: -272M Q2 '25: -261.4M Q3 '25: -248.5M Q4 '25: -235.5M Q1 '26: -213.4M Q2 '26: -212.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '20: -87.9M Q3 '20: -92.4M Q4 '20: -104.4M Q1 '21: -34.9M Q2 '21: -42.2M Q3 '21: -72.6M Q4 '21: -77.9M Q1 '22: -176M Q2 '22: -206.4M Q3 '22: -219.7M Q4 '22: -238.6M Q1 '23: -255.6M Q2 '23: -266.8M Q3 '23: -274.5M Q4 '23: -304.4M Q1 '24: -287.5M Q2 '24: -283.2M Q3 '24: -282.6M Q4 '24: -251.1M Q1 '25: -272.6M Q2 '25: -262.1M Q3 '25: -248.9M Q4 '25: -235.9M Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q3 '21: 92.7M Q1 '22: 108.3M Q2 '22: 108.6M Q3 '22: 110.9M Q1 '23: 121.3M Q2 '23: 121.7M Q3 '23: 122.2M Q1 '24: 130.8M Q2 '24: 132.8M Q3 '24: 140.2M Q1 '25: 169.2M Q2 '25: 171.3M Q3 '25: 172.4M Q1 '26: 179.8M Q2 '26: 202.8M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-27.00 -18.00 -9.00 0.00 9.00 18.00 27.00 Q4 '19: -21.82 Q1 '20: -23.16 Q2 '20: -23.94 Q3 '20: -21.41 Q4 '20: -5.40 Q1 '21: 0.12 Q2 '21: 4.08 Q3 '21: 6.42 Q4 '21: -3.85 Q1 '22: -3.95 Q2 '22: -2.56 Q3 '22: -2.66 Q4 '22: -2.59 Q1 '23: -2.80 Q2 '23: -2.90 Q3 '23: -2.68 Q4 '23: -2.80 Q1 '24: -2.64 Q2 '24: -2.52 Q3 '24: -2.61 Q4 '24: -2.36 Q1 '25: -2.20 Q2 '25: -1.92 Q3 '25: -1.72 Q4 '25: -1.61 Q1 '26: -1.56 Q2 '26: -1.56 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.